GPH and GLMD Related Headlines
Go Back- Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
- Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
- Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
GPH and GLMD Related Press Releases
Go Back- Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
- Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
- Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
